Analysis of initial baseline clinical parameters and treatment strategy associated with medication failure in the treatment of benign prostatic hyperplasia in Korea.
OBJECTIVE
To analyze the baseline clinical factors and medication treatment strategy used in cases with medication treatment failure of benign prostatic hyperplasia (BPH).


METHODS
From January 2006 to December 2009, 677 BPH patients with at least 3 months of treatment with medication were enrolled. We analyzed clinical factors by medication failure (n=161) versus maintenance (n=516), by prostate size (less than 30 g, n=231; 30 to 50 g, n=244; greater than 50 g, n=202), and by prostate-specific antigen (PSA) levels (less than 1.4 ng/mL, n=324; more than 1.4 ng/mL, n=353).


RESULTS
Age, combination medication rate, PSA, and prostate volume were statistically different between the medication treatment failure and maintenance groups. By prostate size, the PSA and medication failure rates were relatively higher and the medication period was shorter in patients with a prostate size of more than 30 g. The combination medication rate was higher in patients with a prostate size of more than 50 g. The medication failure rate and prostate volume were higher in patients with a PSA level of more than 1.4 ng/mL. However, the combination treatment rate was not significantly different in patients with a PSA level lower than 1.4 ng/mL. Suggestive cutoffs for combination medication are a prostate volume of 34 g and PSA level of 1.9 ng/mL.


CONCLUSIONS
The clinical factors associated with medication failure were age, treatment type, and prostate volume. Combination therapy should be considered more in Korea in patients with a PSA level higher than 1.4 ng/mL and a prostate volume of between 30 and 50 g to prevent medication failure.
Department of Urology, Konyang Universtiy College of Medicine, Daejeon, Korea.
Hoon
H
Choi
Young-Seop
YS
Chang
Jin-Bum
JB
Kim
Seok Ho
SH
Kang
Hong Seok
HS
Park
Jeong Gu
JG
Lee
Urology. 2005 Oct;66(4):780-8
16230138
Eur Urol. 2003 Jul;44(1):94-9; discussion 99-100
12814681
Urology. 2001 Aug;58(2):210-6
11489703
J Urol. 1997 Aug;158(2):481-7
9224329
Eur Urol. 2001 Apr;39(4):390-9
11306876
Eur Urol. 2004 Nov;46(5):547-54
15474261
N Engl J Med. 2003 Dec 18;349(25):2387-98
14681504
Urology. 2002 Sep;60(3):434-41
12350480
N Engl J Med. 1996 Aug 22;335(8):533-9
8684407
Int J Clin Pract. 2008 Jul;62(7):1076-86
18479366
Urology. 2003 Jan;61(1):119-26
12559281
Rev Urol. 2005;7 Suppl 9:S3-S14
16985902
N Engl J Med. 1998 Feb 26;338(9):557-63
9475762
Int J Clin Pract. 2008 Jan;62(1):18-26
18028388